

For assistance, contact your pharmacy representative: \_\_\_\_\_ Phone: \_\_\_\_\_ (For providers only)

**PLEASE CONSIDER SENDING YOUR PRESCRIPTION ELECTRONICALLY. ALL OF OUR PHARMACY LOCATIONS ACCEPT ELECTRONIC PRESCRIPTIONS.**

Note: This form is intended for prescriber use only, if faxed, the fax must come from MD office or hospital (may not be faxed by patient).



**Rheumatoid Arthritis**  
Prescription/Pharmacy Intake Form

Central Pharmacy: \_\_\_\_\_  
 Retail/Community Pharmacy Fax: \_\_\_\_\_ Pharmacy Phone: \_\_\_\_\_  
Date Needed: \_\_\_\_\_ Ship To:  Prescriber's Office  Patient's Home  Other: \_\_\_\_\_

**PATIENT INFORMATION**

Patient name: \_\_\_\_\_ DOB: \_\_\_\_\_  Male  Female  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip code: \_\_\_\_\_  
Phone # (Daytime): \_\_\_\_\_ Phone # (Evening): \_\_\_\_\_  
E-mail Address: \_\_\_\_\_ Case Manager: \_\_\_\_\_

Insurance provider (Please include copy of front and back of card): \_\_\_\_\_  
ID #: \_\_\_\_\_ Policy/Group #: \_\_\_\_\_ Phone #: \_\_\_\_\_  Patient is eligible for Medicare  
Name of Insured: \_\_\_\_\_ Employer: \_\_\_\_\_  
Relationship to Patient:  Self  Other: \_\_\_\_\_ Prescription Card:  Yes  No Carrier: \_\_\_\_\_ Policy/Group #: \_\_\_\_\_

Will there be access to anaphylactic medications and oxygen at the administration site? \_\_\_\_\_

**CLINICAL ASSESSMENT – Please complete ALL sections to avoid delays in filling prescription**

Patient is new to therapy  Patient is currently on therapy Start date: \_\_\_\_\_  Physician Provides Injection Training Injection/Infusion Date: \_\_\_\_\_  
Primary Diagnosis Code and Condition (ICD-10): \_\_\_\_\_ Other Diagnosis/Conditions: \_\_\_\_\_  
Joints Affected: \_\_\_\_\_ Number of Tender Joints: \_\_\_\_\_ Number of Swollen Joints: \_\_\_\_\_ Current Weight: \_\_\_\_\_ Date: \_\_\_\_\_  
 New Therapy Induction  Therapy Change  Therapy Continuation | Weeks Completed  0  2  4  6 | Stop Date: \_\_\_\_\_  
ESR: \_\_\_\_\_ Date: \_\_\_\_\_ CRP: \_\_\_\_\_ Date: \_\_\_\_\_ TB Results: \_\_\_\_\_ Date: \_\_\_\_\_

Allergies: \_\_\_\_\_

Medication	Dose/Directions/Frequency	Quantity	Refills
<b>Actemra (tocilizumab)</b> <input type="checkbox"/> 162mg Syringe <input type="checkbox"/> 80mg/4mL Vial <input type="checkbox"/> 200mg/10mL Vial <input type="checkbox"/> 400mg/20mL Vial			
<b>Cimzia (certolizumab pegol)</b> <input type="checkbox"/> (6) 200mg starter kit <input type="checkbox"/> (2) 200mg Syringe <input type="checkbox"/> (2) 200mg Vial			
<b>Enbrel (etanercept)</b> <input type="checkbox"/> 25mg Syringe <input type="checkbox"/> 25mg Vial <input type="checkbox"/> 50mg Syringe <input type="checkbox"/> 50mg SureClick™ Pen <input type="checkbox"/> 50mg Mini™ Cartridge			
<b>Humira (adalimumab)</b> <input type="checkbox"/> 10mg Syringe <input type="checkbox"/> 20mg Syringe <input type="checkbox"/> 40mg Syringe <input type="checkbox"/> 40mg Pen			
<b>Kezara (sarilumab)</b> <input type="checkbox"/> 150mg Syringe <input type="checkbox"/> 200mg Syringe			
<b>Orencia (abatacept)</b> <input type="checkbox"/> 50mg Prefilled Syringe <input type="checkbox"/> 87.5mg Prefilled Syringe <input type="checkbox"/> 125mg Clickject Pen <input type="checkbox"/> 125mg Prefilled Syringe <input type="checkbox"/> 250mg Vial			
<b>Inflectra (infliximab-dyyb)</b> <input type="checkbox"/> 100mg Vial			
<b>Remicade (infliximab)</b> <input type="checkbox"/> 100mg Vial			
<b>Rituxan (rituximab)</b> <input type="checkbox"/> 100mg Vial <input type="checkbox"/> 500mg Vial			
<b>Simponi (golimumab)</b> <input type="checkbox"/> 50mg Syringe <input type="checkbox"/> 50mg Smartject	<b>Simponi Aria (golimumab)</b> <input type="checkbox"/> 50mg Vial		
<b>Xeljanz (tofacitinib)</b> <input type="checkbox"/> 5mg Tablet	<b>Xeljanz XR (tofacitinib)</b> <input type="checkbox"/> 11mg Tablet		
<b>Methotrexate</b> – Can only be ordered as combined therapy with one of the above drugs. <input type="checkbox"/> 2.5mg Tablet			
<b>Other</b> <input type="checkbox"/>			

I authorize, by my signature below, the dispensing of appropriate needles and syringes, in a sufficient quantity, required for the administration of injectable products by patient or caregiver. Authorization for supplies runs concurrently with the number of refills or time frame specified for the drug.

**PRESCRIBER INFORMATION**

Prescriber's name: \_\_\_\_\_ Practice/facility: \_\_\_\_\_  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip code: \_\_\_\_\_  
Office contact: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
Email: \_\_\_\_\_ Best time to call: \_\_\_\_\_ Preferred method of contact:  Email  Phone  Fax  
State license #: \_\_\_\_\_ DEA #: \_\_\_\_\_ NPI #: \_\_\_\_\_ Medicaid UPIN #: \_\_\_\_\_

In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary" or your state specific required language after their signature. I certify that the above therapy is medically necessary and that the information above is accurate to the best of my knowledge. Prescriber's signature required on one of the lines below.

\_\_\_\_\_ Dispense as written \_\_\_\_\_ Substitution permitted \_\_\_\_\_ Date

The prescriber is to comply with his/her state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber. The document(s) accompanying this transmission may contain confidential health information that is legally protected. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless permitted or required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. Drug names are the property of their respective owners. ©2017 All rights reserved. 113017